Research Areas

The cash keeps flowing for the dominant players in developing RNAi therapies, as evidenced recently by a multi-year strategic alliance between pharma giant GlaxoSmithKline and siRNA specialist Sirna Therapeutics Inc. that has the potential to pump more than $700 million into Sirna coffers.

After a string of acquisition including Innovata’s gene expression technology and the companies LINCO and Cytomyx, Atlanta-based Serologicals Corp. is itself being acquired by Millipore Corp. in a $1.4 billion deal.

As mouse models of human disease become more important in drug discovery,

Key to cell biology is the ability to introduce exogenous DNA into cells, but physicochemical methods such as transfection or electroporation often exhibit low efficiencies and can lead to cell damage.

Further expanding commercialization of European products

The Fine Chemicals division of Sigma-Aldrich (SAFC)

Bioinformatics specialist DNASTAR

One of the great things about being an editor for international trade publications

When we were kids, we were invincible—or so we thought.

Personalized medicine—and personalized vaccines, in particular—have generated tremendous interest. Each vaccine must be custom-made for each patient, so for each patient more work must be done than is required for “off-the-shelf” vaccines. What are needed now are methods that enable the manufacture of such products in an affordable and efficient manner.